Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne
17 October 2016 - 11:15PM
Targadox™ Is Journey’s Fourth Launched
Product in the Past 12 Months
Journey Medical Corporation, a Fortress Biotech, Inc. (NASDAQ:FBIO)
company, launched Targadox™ (doxycycline hyclate USP) 50 mg film
coated tablets indicated as adjunctive therapy for the treatment of
severe acne. Targadox™ is the only 50 mg immediate-release
doxycycline hyclate tablet currently available on the market.
Targadox™ is available by prescription at major U.S. retail and
specialty pharmacy chains. According to Symphony Health,
doxycycline is the most-prescribed oral antibiotic in Dermatology
with more than 3.7 million prescriptions written in 2015.
Acne is one of the most commonly treated disease states in
dermatology. Doxycycline has both anti-inflammatory and
antibacterial properties, two important characteristics for a
medication in the treatment of acne. According to the American
Academy of Dermatology 2016 “Guidelines of care for the
management of acne vulgaris,” systemic antibiotics are recommended
in the management of moderate and severe acne and forms of
inflammatory acne that are resistant to topical treatments. Oral
antibiotics should be used in combination with a topical retinoid
and benzoyl peroxide.
Claude Maraoui, President and CEO of Journey Medical
Corporation, said, “Launching four products in one year is a
significant achievement for any size company. As a growing startup
company, we credit the significant experience of our team and
strategic allocation of resources for the achievement of this
milestone. By targeting one of the most commonly treated
diseases in dermatology, we expect Targadox™ will become our
flagship brand in the near-term, as we continue to develop and
commercialize dermatologic therapies for the future.”
Dr. Lindsay Rosenwald, Chairman and CEO of Fortress Biotech,
said, “Journey Medical’s success in launching its fourth product
this year is a testament to the leadership team’s expertise and
dedication. As Fortress Biotech continues to implement its strategy
of acquiring, developing and commercializing novel pharmaceutical
and biotechnology products, Journey Medical exemplifies what we
believe is a winning business model.”
About Journey Medical Corporation
Journey Medical Corporation (JMC), headquartered in Scottsdale,
Arizona, is focused on developing, acquiring, licensing and
commercializing branded dermatology products. It is a subsidiary of
Fortress Biotech, Inc. For more information about Journey,
visit www.jmcderm.com.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical
company dedicated to acquiring, developing and commercializing
novel pharmaceutical and biotechnology products. Fortress plans to
develop and commercialize products both within Fortress and through
subsidiary companies, also known as Fortress Companies.
Fortress intends to leverage its biopharmaceutical business
expertise and drug development capabilities to help the Fortress
Companies achieve their goals. Additionally, Fortress intends
to provide funding and management services to each of the Fortress
Companies and, from time to time, Fortress and the Fortress
Companies will seek licensing, acquisitions, partnerships, joint
ventures and/or public and private financings to accelerate and
provide additional funding to support their research and
development programs. For more information, visit
www.fortressbiotech.com.
Forward-Looking Statements
This press release may contain “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
growth strategy and product development programs and any other
statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: risks related to our growth
strategy; risks related to our ability to innovate, develop and
continue to commercialize pharmaceutical and biotechnology
products; our ability to attract, integrate, and retain key
personnel; risks relating to the results of research and
development activities; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
Contacts:
Journey Medical Corporation
Claude Maraoui, President & CEO
480-434-6670; contact@jmcderm.com
Fortress Biotech, Inc.
Lucy Lu, MD, Executive Vice President & Chief Financial Officer
781-652-4500; ir@fortressbiotech.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From May 2023 to May 2024